Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Immune-mediated Necrotizing Myopathy (IMNM) Clinical Trials

2 recruiting trials for Immune-mediated Necrotizing Myopathy (IMNM). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
2
Total Trials
2
Recruiting Now
0
Phase 3 Trials
2
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06249438

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients...

Sponsor: RenJi HospitalEnrolling: 301 location
RECRUITINGPhase 1NCT06371417

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of...

Sponsor: Chugai PharmaceuticalEnrolling: 14420 locations

Explore Other Conditions

Obesity — 145 recruiting
Colorectal Cancer — 132 recruiting
Stroke — 131 recruiting
Depression — 128 recruiting

Frequently Asked Questions

There are currently 2 clinical trials for Immune-mediated Necrotizing Myopathy (IMNM), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Immune-mediated Necrotizing Myopathy (IMNM), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Immune-mediated Necrotizing Myopathy (IMNM), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.